Moore K, Colombo N, Scambia G, et al. Olaparib maintenance therapy following first-line platinum-based chemotherapy in patients with FIGO stage III–IV ovarian cancer (OC) with a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. ESMO 2018, abstract LBA7_PR.
Is neoadjuvante immuuntherapie een optie bij hormoongevoelige borstkanker?
jul 2024 | Borstkanker